Welcome to our dedicated page for Rapt Therapeutics SEC filings (Ticker: RAPT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The RAPT Therapeutics, Inc. (Nasdaq: RAPT) SEC filings page on Stock Titan provides access to the company’s official reports and disclosures filed with the U.S. Securities and Exchange Commission. As a clinical-stage immunology-based biopharmaceutical company focused on inflammatory and immunological diseases, RAPT uses SEC filings to report financial results, capital-raising activities and other material corporate events.
Investors can review current and historical Form 8-K filings in which RAPT reports items such as quarterly and year-to-date financial results, underwritten public offerings of common stock, and changes to its board of directors and governance arrangements. For example, recent 8-K filings have furnished press releases detailing net losses, research and development and general and administrative expenses, cash and marketable securities balances, and the terms and expected proceeds of a public equity offering intended to fund operations into 2028 based on the company’s stated operating plans.
Beyond 8-Ks, RAPT’s broader SEC reporting (such as Forms 10-Q and 10-K, referenced in its press releases) contains more extensive discussions of risk factors, pipeline programs, clinical trial status and accounting policies. These periodic reports are important for understanding how the company describes its clinical-stage immunology-based business model, including programs like ozureprubart and other early-stage assets, as well as its assessment of capital needs and potential risks.
On Stock Titan, SEC filings are updated in near real time as they are posted to the EDGAR system. AI-powered summaries help explain the key points of lengthy documents, highlighting items such as changes in operating expenses, financing transactions, and material clinical or regulatory disclosures described in attached press releases or narrative sections. Users can quickly scan these summaries before diving into the full text of a filing.
For those tracking executive and director matters, RAPT’s filings also include information on board appointments, committee assignments and compensation policies, as seen in governance-related 8-K disclosures. Together, these documents provide a structured record of how RAPT communicates its financial condition, capital structure and development progress to regulators and the market.
GSK plc, through subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co., has launched an all-cash tender offer to acquire RAPT Therapeutics, Inc.. The offer is for $58.00 per share for each share of RAPT common stock, payable in cash without interest and subject to withholding taxes.
The offer covers all outstanding RAPT common shares and is made pursuant to an Agreement and Plan of Merger dated January 19, 2026. RAPT has advised that 30,922,702 shares of common stock were issued and outstanding as of the close of business on January 28, 2026.
GSK plc, through subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co., has filed pre-commencement materials for a planned cash tender offer to acquire all issued and outstanding shares of RAPT Therapeutics, Inc. common stock under an Agreement and Plan of Merger dated January 19, 2026.
The tender offer has not yet started. Once it begins, GSK and its affiliates will file a full tender offer statement on Schedule TO, and RAPT will file a Schedule 14D-9 explaining the board’s recommendation. Stockholders are urged in the communication to read these future documents carefully when available, as they will contain detailed terms of the offer, conditions to closing and other important information, alongside extensive forward-looking statement and risk-factor disclosures about the proposed acquisition and related clinical and regulatory expectations.
RAPT Therapeutics, Inc. is the target of a planned acquisition by GSK plc, which intends to launch a cash tender offer for all issued and outstanding shares of RAPT common stock. The transaction will be carried out through GSK’s subsidiaries GlaxoSmithKline LLC and Redrose Acquisition Co. under an Agreement and Plan of Merger dated January 19, 2026.
The filing is a pre-commencement communication, meaning the tender offer has not yet begun. Once it starts, GSK will file a detailed Schedule TO and RAPT will file a Schedule 14D‑9, providing terms of the offer and the board’s recommendation. The document also includes extensive forward‑looking statement disclosures, highlighting risks such as timing of the offer, satisfaction of closing conditions, required regulatory approvals, potential termination of the merger agreement and possible business disruptions if the deal does not close.
RAPT Therapeutics, Inc. entered into a definitive Agreement and Plan of Merger with GlaxoSmithKline LLC under which a GSK subsidiary will launch a cash tender offer to acquire all outstanding RAPT common shares at $58.00 per share, without interest and subject to withholding taxes. Completion of the offer is conditioned on a majority of RAPT shares being tendered and on required antitrust clearances under the HSR Act, among other customary conditions. After the offer closes, the buyer’s subsidiary will merge into RAPT, which will become a wholly owned GSK subsidiary, and remaining shares will receive the same cash price. The agreement includes a $78.4 million termination fee payable by RAPT in certain circumstances and a $100.8 million reverse termination fee payable by GSK if specified regulatory-related conditions are not met by the contractual end date.
RAPT Therapeutics, Inc. filed a current report to let investors know that the company will participate in the 44th Annual J.P. Morgan Healthcare Conference on January 14, 2026. The company is providing its conference presentation as Exhibit 99.1, described as a corporate presentation, and making it available for transparency under Regulation FD, which governs fair disclosure of information to investors. The report also clarifies that the presentation and related information are being furnished rather than filed, meaning they are not subject to certain liability provisions of the securities laws and are not automatically incorporated into other SEC filings unless specifically referenced.
RAPT Therapeutics (RAPT) filed its Q3 2025 10-Q, reporting a net loss of $17.6 million for the quarter and $52.4 million year-to-date as the company advances its immunology pipeline. Operating expenses were $19.4 million in Q3, led by research and development of $12.0 million and general and administrative of $7.3 million. Other income contributed $1.8 million in the quarter.
Liquidity remains solid with $157.3 million in cash, cash equivalents and marketable securities as of September 30, 2025, and operating cash outflows of $76.1 million for the nine months. After quarter end, RAPT completed an underwritten offering of 8,333,334 shares at $30.00 per share for net proceeds of approximately $234.4 million, bolstering its cash resources. Shares outstanding were 27,710,871 as of November 3, 2025.
The company initiated the prestIgE Phase 2b trial of ozureprubart in food allergy and announced positive topline data from Jeyou’s Phase 2 ozureprubart trial in chronic spontaneous urticaria, where dosing every 8 or 12 weeks showed comparable efficacy to omalizumab dosed every 4 weeks. RAPT also effected a 1‑for‑8 reverse stock split in June 2025.
RAPT Therapeutics filed an 8‑K stating it furnished a press release announcing financial results for the quarter and nine months ended September 30, 2025. The release is included as Exhibit 99.1.
The company states the Item 2.02 information and Exhibit 99.1 are furnished, not filed, and are not incorporated by reference into other SEC filings.
RAPT Therapeutics announced an underwritten public offering of 8,333,334 shares of common stock at $30.00 per share. Underwriters will purchase shares at $28.20 each, and have a 30-day option to buy up to 1,250,000 additional shares.
The company estimates net proceeds of $234.4 million, or $269.7 million if the option is fully exercised. RAPT states that these proceeds, together with existing cash, cash equivalents and marketable securities, are expected to fund operations into 2028. Closing is expected on October 23, 2025, subject to customary conditions. The offering is being made under an effective Form S-3 and prospectus supplement.
RAPT Therapeutics launched a primary offering of 8,333,334 shares of common stock at $30.00 per share. Underwriters have a 30‑day option to purchase up to 1,250,000 additional shares at the public price, less discounts.
Gross proceeds are $250,000,020 with underwriting discounts of $15,000,001, yielding proceeds to the company before expenses of $235,000,019. RAPT estimates net proceeds of approximately $234.4 million (or $269.7 million if the option is fully exercised). The company intends to use the funds to advance RPT904 in food allergies and chronic spontaneous urticaria, support other pipeline programs, and for working capital and general corporate purposes. Based on current plans, cash including these proceeds is expected to fund operations into 2028.
Shares outstanding were 16,536,069 as of June 30, 2025; this is a baseline figure, not the amount being offered.
RAPT Therapeutics (RAPT) launched a primary offering of common stock via a preliminary prospectus supplement under its Form S-3 shelf. The filing includes a 30-day option for underwriters to purchase additional shares at the public offering price, less underwriting discounts and commissions. RAPT’s stock trades on Nasdaq as “RAPT”; the last reported sale price was $33.67 per share on October 20, 2025.
RAPT intends to use net proceeds, together with existing cash, to advance RPT904 in food allergies and chronic spontaneous urticaria (CSU), support other pipeline initiatives, and for working capital and general corporate purposes. Shares outstanding were 16,536,069 as of June 30, 2025.
RAPT and Jeyou reported positive topline Phase 2 CSU data for RPT904, showing numerically greater UAS7 improvements and higher UAS7=0 rates at Weeks 8, 12 and 16 versus omalizumab, with no serious adverse events related to study drug and no treatment-related discontinuations. The companies plan to discuss Phase 3 development with regulators and to initiate a Phase 2b trial in food allergies before the end of 2025.